Open AccessReal-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings
Author(s) -
Silvia Rosati,
Alexander Wong,
V. Di Marco,
Paco Pérez-Hernandez,
Guilherme Macedo,
Christian Brixko,
Roberto Ranieri,
Francesca Campanale,
Annalisa Basciá,
Conrado FernándezRodríguez,
Victor de Lédinghen,
Ivana Maida,
Elisabetta Teti,
Alessandra Mangia,
Kim Vanstraelen,
Cándido Márquez Hernández,
Michael Mertens,
Ιωάννα Ντάλλα,
Heribert Ramroth,
Elena Garza Jiménez
Publication year - 2022
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/fvl-2022-0016
Subject(s) - prison , medicine , sofosbuvir , hepatitis c virus , guideline , hepatitis c , population , mental health , psychiatry , intensive care medicine , virology , ribavirin , virus , psychology , environmental health , pathology , criminology
Background: People in prison are at high risk of hepatitis C virus (HCV) infection and often have a history of injection drug use and mental health disorders. Simple test-and-treat regimens which require minimal monitoring are critical. Methods: This integrated real-world analysis evaluated the effectiveness of once daily sofosbuvir/velpatasvir (SOF/VEL) in 20 prison cohorts across Europe and Canada. The primary outcome was sustained virological response (SVR) in the effectiveness population (EP), defined as patients with a valid SVR status. Secondary outcomes were reasons for not achieving SVR, adherence and time between HCV RNA diagnosis and SOF/VEL treatment. Results: Overall, 526 people in prison were included with 98.9% SVR achieved in the EP (n = 442). Cure rates were not compromised by drug use or existence of mental health disorders. Conclusion: SOF/VEL for 12 weeks is highly successful in prison settings and enables the implementation of a simple treatment algorithm in line with guideline recommendations and test-and-treat strategies.